ResApp Health Limited announced that it has agreed to a 12 month extension to its commercial licence agreement with Medgate AG ("Medgate") to use ResApp's smartphone-based acute respiratory diagnostic test, ResAppDx, on Medgate's telehealth platform. ResApp's acute respiratory diagnostic test, ResAppDx, uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. ResAppDx is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia.

Medgate plans to also expand the use of ResAppDx across additional patient journeys in its telemedicine services and will expand use into Germany in 2023.